We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-21.88%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$397M
AUM Growth
-$118M
Cap. Flow
+$42.4M
Cap. Flow %
10.67%
Top 10 Hldgs %
64.21%
Holding
58
New
7
Increased
4
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$16.7M
2
ZYME icon
Zymeworks
ZYME
+$8.65M
3
SRRK icon
Scholar Rock
SRRK
+$5.8M
4
ALXO icon
ALX Oncology
ALXO
+$4.49M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$4.08M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$4.64M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$518K
3
NKTX icon
Nkarta
NKTX
+$11

Sector Composition

Rank Sector Weight
1 Healthcare 97.57%
2 Financials 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$75.1M 18.91%
4,591,888
– –
LENZ
2
LENZ Therapeutics
LENZ
$172M
$41.2M 10.36%
1,153,229
+31,524
+3% +$1.97M
NKTX icon
3
Nkarta
NKTX
$162M
$23.2M 5.83%
2,034,702
-1
-0% -$11
TIL icon
4
Instil Bio
TIL
$48.4M
$21.4M 5.39%
99,598
– –
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$21.2M 5.35%
1,262,551
– –
CNTA
6
DELISTED
Centessa Pharmaceuticals
CNTA
$16.9M 4.25%
1,884,096
+424,403
+29% +$3.87M
FMTX
7
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$14.6M 3.67%
1,565,526
– –
ACLX
8
DELISTED
Arcellx
ACLX
$14M 3.53%
+999,727
New +$16.7M
STRO icon
9
Sutro Biopharma
STRO
$379M
$13.8M 3.47%
167,558
– –
ACRS icon
10
Aclaris Therapeutics
ACRS
$730M
$13.7M 3.45%
794,171
– –
ICPT
11
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$10.4M 2.62%
640,688
– –
RAIN
12
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$7.97M 2.01%
1,571,379
– –
ZYME icon
13
Zymeworks
ZYME
$1.68B
$6.36M 1.6%
+970,987
New +$8.65M
IOBT
14
DELISTED
IO Biotech
IOBT
$5.94M 1.49%
1,120,437
– –
JANX icon
15
Janux Therapeutics
JANX
$935M
$5.91M 1.49%
411,871
– –
EYPT icon
16
EyePoint Inc
EYPT
$1.02B
$5.83M 1.47%
480,000
– –
VRNA
17
DELISTED
Verona Pharma
VRNA
$5.54M 1.4%
1,111,112
– –
JYAC
18
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.98M 1.25%
507,041
– –
SNCE
19
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$4.82M 1.21%
45,000
– –
IMCR icon
20
Immunocore
IMCR
$1.78B
$4.81M 1.21%
160,963
+96,963
+152% +$2.45M
TNGX icon
21
Tango Therapeutics
TNGX
$4.34B
$4.78M 1.2%
630,000
– –
AVDL
22
DELISTED
Avadel Pharmaceuticals
AVDL
$4.5M 1.13%
659,409
– –
ALXO icon
23
ALX Oncology
ALXO
$273M
$4.44M 1.12%
+262,786
New +$4.49M
SRRK icon
24
Scholar Rock
SRRK
$5.71B
$4.38M 1.1%
+339,611
New +$5.8M
DICE
25
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$4.37M 1.1%
+228,466
New +$4.08M
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q1 2022 Portfolio in Review

As of Q1 2022, Samsara BioCapital held 58 positions worth $397M, down 23% from $515M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Samsara BioCapital deployed $42.4M of net new capital in Q1 2022, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Arcellx: 999,727 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $4.64M trimmed.

  • Samsara BioCapital's largest Q1 2022 buy was Arcellx: 999,727 shares worth $14M.
  • Samsara BioCapital added most to Centessa Pharmaceuticals in Q1 2022, an estimated $3.87M increase.
  • Samsara BioCapital's biggest Q1 2022 reduction was SpringWorks Therapeutics, cutting an estimated $4.64M.
  • Samsara BioCapital's ten largest holdings make up 64% of its $397M portfolio in Q1 2022.
  • Samsara BioCapital opened 7 new positions and closed 1 in Q1 2022.
  • Samsara BioCapital's portfolio value fell 23% quarter-over-quarter to $397M.

Based on Samsara BioCapital's 13F filing for Q1 2022, filed 16 May 2022.